| Biomarker ID | 467 |
| PMID | 19542190 |
| Year | 2009 |
| Biomarker | IGF-I/IGFBP-3 |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated after Polyphenon E treatment(3.4%) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(IGF1):- Skeletal myogenesis control by HDAC and calcium/calmodulin-dependent kinase (CaMK),BAD phosphorylation regulation,Fibroblast growth factor 1,IGF1 signaling pathway,IGF1 receptor signaling through beta-arrestin |
| Experiment | Before Vs After Polyphenon E treatment |
| Type of Biomarker | Predictive |
| Cohort | Twenty-six men with positive prostate biopsies, scheduled for radical prostatectomy were given daily doses of Polyphenon E, to detect the affect of the drug. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.028 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IGF1: IGFBP3 |